SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation.

Saved in:

Bibliographic Details
Title:	SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation.
Authors:	Lamerton RE; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom., Marcial-Juarez E; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Faustini SE; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Perez-Toledo M; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Goodall M; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Jossi SE; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Newby ML; School of Biological Sciences, University of Southampton, Southampton, United Kingdom., Chapple I; Periodontal Research Group, School of Dentistry, Institute of Clinical Sciences, University of Birmingham, and Birmingham Community Healthcare National Health Service Trust, Birmingham, United Kingdom., Dietrich T; Periodontal Research Group, School of Dentistry, Institute of Clinical Sciences, University of Birmingham, and Birmingham Community Healthcare National Health Service Trust, Birmingham, United Kingdom., Veenith T; Department of Critical Care Medicine, University Hospitals Birmingham National Health Service (NHS) Trust, Birmingham, United Kingdom., Shields AM; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Harper L; Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom., Henderson IR; Institute for Molecular Bioscience, University of Queensland, St Lucia, QLD, Australia., Rayes J; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom., Wraith DC; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Watson SP; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom., Crispin M; School of Biological Sciences, University of Southampton, Southampton, United Kingdom., Drayson MT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Richter AG; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Cunningham AF; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Source:	Frontiers in immunology [Front Immunol] 2022 Jul 04; Vol. 13, pp. 838780. Date of Electronic Publication: 2022 Jul 04 (Print Publication: 2022).
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-3224
DOI:	10.3389/fimmu.2022.838780